Current NDC auxiliary source row compounder:1865

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 26436-5632
Product Ndc: 26436-5632
Product Ndc Digits: 264365632
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: CCDB
Proprietary Name Suffix: [empty]
Nonproprietary Name: Ciprofloxacin 40.7% Clotrimazole 40.7% Dexamethasone 3.4% Boric acid 15.2%
Dosage Form Name: POWDER
Route Name: AURICULAR (OTIC)
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Hybrid Pharma
Establishment Name: Hybrid Pharma
Establishment Fei: [empty]
Substance Name: CIPROFLOXACIN; DEXAMETHASONE; CLOTRIMAZOLE
Active Ingredients Info: 407 mg/1 g; 34 mg/1 g; 407 mg/1 g
History Active Ingredients Raw: CIPROFLOXACIN; DEXAMETHASONE; CLOTRIMAZOLE
History Active Ingredients Info Raw: 407 mg/1 g; 34 mg/1 g; 407 mg/1 g
History Dosage Raw: POWDER
Dea Schedule: [empty]
Package Ndc Raw: 26436-5632-5
Package Ndc: 26436-5632-5
Package Ndc Digits: 2643656325
Package Ndc11: 26436563205
Package Description: 5 g in 1 JAR (26436-5632-5)
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:1865
Source Row Number: 1865
Source Row Hash: 57e7377e6ef0874a8400718f69d1316332bf7a70df10291bb209e559190cde8b
Import Run Id: 20261022T045816Z
Loaded At: 2026-10-22 05:03:38

Exact raw FDA source fields#

{
    "ROUTENAME": "AURICULAR (OTIC)",
    "PRODUCTNDC": "26436-5632",
    "DEASCHEDULE": "",
    "LABELERNAME": "Hybrid Pharma",
    "SUBSTANCENAME": "CIPROFLOXACIN; DEXAMETHASONE; CLOTRIMAZOLE",
    "DOSAGEFORMNAME": "POWDER",
    "NDCPACKAGECODE": "26436-5632-5",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "CCDB",
    "REPORTINGPERIOD": "2024-2",
    "NONPROPRIETARYNAME": "Ciprofloxacin 40.7% Clotrimazole 40.7%  Dexamethasone 3.4% Boric acid 15.2%",
    "PACKAGEDESCRIPTION": "5 g in 1 JAR (26436-5632-5) ",
    "ACTIVEINGREDIENTSINFO": "407 mg/1 g; 34 mg/1 g; 407 mg/1 g",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:1865
Source Row Number: 1865
Status Scope: package
Lookup Ndc: 26436-5632-5
Lookup Ndc Digits: 2643656325
Product Ndc: 26436-5632
Product Ndc Digits: 264365632
Package Ndc: 26436-5632-5
Package Ndc Digits: 2643656325
Package Ndc11: 26436563205
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2024-2
Reporting Period: 2024-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 57e7377e6ef0874a8400718f69d1316332bf7a70df10291bb209e559190cde8b
Import Run Id: 20261022T045816Z
Loaded At: 2026-10-22 05:03:38